The Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK have published guidelines for annual follow up of patients with metal on metal hip replacements following widespread concern regarding metallosis We followed up 718 total hip replacements (594 stemmed hips and 124 resurfacing) with metal on metal bearing, implanted between April 1999 and August 2010 in dedicated clinics with clinical and radiological assessment along with assessment of serum metal ions. Survival was calculated using Kaplan Meier analysis.Introduction
Methods
Drug therapy forms an integral part of the management
of many orthopaedic conditions. However, many medicines can produce
serious adverse reactions if prescribed inappropriately, either
alone or in combination with other drugs. Often these hazards are
not appreciated. In response to this, the European Union recently
issued legislation regarding safety measures which member states
must adopt to minimise the risk of errors of medication. In March 2014 the Medicines and Healthcare products Regulatory
Agency and NHS England released a Patient Safety Alert initiative
focussed on errors of medication. There have been similar initiatives
in the United States under the auspices of The National Coordinating
Council for Medication Error and The Joint Commission on the Accreditation
of Healthcare Organizations. These initiatives have highlighted
the importance of informing and educating clinicians. Here, we discuss common drug interactions and contra-indications
in orthopaedic practice. This is germane to safe and effective clinical
care. Cite this article:
Serum lactate has been shown to be an indicator of adverse clinical outcomes in patients admitted secondary to general trauma or sepsis. We retrospectively investigated whether admission serum venous lactate can predict in-hospital mortality in patients with hip fractures. Over a 38-month period the admission venous lactate of 807 patients with hip fractures was collated. Mean age was 82 years. The overall in-hospital mortality for this cohort was 9.4%. Mortality was not influenced by the fracture pattern or the type of surgery - be it internal fixation or arthroplasty (p = 0.7). A critical threshold of 3 mmol/L with respect to the influence of venous lactate level on mortality was identified. Mortality rate in those with a lactate level of less than 3 mmol/L was 8.6% and 14.2% for those whose level was 3 mmol/L or greater. A 1 mmol/L increase in venous lactate was associated with a 1.2 (1.02–1.41) increased risk of in-hospital mortality. Patients with a venous lactate of 3 mmol/L or higher had twice the odds of death in hospital compared to matched individuals. There was no statistically significant difference in ASA distribution between those with a lactate of less than or greater than 3 mmol/L.Background and Purpose
Method and Results
Cauda equina syndrome (CES) is a physical process. There is compression of the cauda equina resulting in arrest of the electrochemical signal from the central nervous system. Previous studies have demonstrated that anthropomorphic features influence nerve conduction properties. We therefore sought to if there was an association between biophysical parameters and CES.Background
Aim
Osteoporosis is common and the health and financial
cost of fragility fractures is considerable. The burden of cardiovascular
disease has been reduced dramatically by identifying and targeting
those most at risk. A similar approach is potentially possible in
the context of fragility fractures. The World Health Organization
created and endorsed the use of FRAX, a fracture risk assessment
tool, which uses selected risk factors to calculate a quantitative,
patient-specific, ten-year risk of sustaining a fragility fracture.
Treatment can thus be based on this as well as on measured bone
mineral density. It may also be used to determine at-risk individuals,
who should undergo bone densitometry. FRAX has been incorporated
into the national osteoporosis guidelines of countries in the Americas,
Europe, the Far East and Australasia. The United Kingdom National
Institute for Health and Clinical Excellence also advocates its
use in their guidance on the assessment of the risk of fragility
fracture, and it may become an important tool to combat the health
challenges posed by fragility fractures.
Large studies have reported high dislocation rates (7 to 24%) following revision total hip arthroplasty (THA), particularly when the revision is undertaken in the presence of pre-existing instability. We retrospectively reviewed the clinical and radiographic outcome of 155 consecutive revision THA's that had been performed using an unconstrained dual-mobility acetabular implant. It features a mobile polyethylene liner articulating with both the prosthesis head and a metal acetabular cup, such that the liner acts as the femoral head in extreme positions. It can be implanted in either a press fit or cemented manner. Mean follow-up was 40 months (18–66) and average age 77 (42–89). Uncemented (n=122) and cemented (n=33) implants with a reinforcing cage, were used. Indications were aseptic loosening (n=113), recurrent instability (n=29), periprosthetic fracture (n=11) and sepsis (n=2). Three of the 155 cases (1.9%) dislocated within 6 weeks of surgery and were successfully managed with closed reduction. The 3 dislocations occurred in the groups revised for recurrent dislocation and periprosthetic fracture. There were no cases of recurrent dislocation and no revisions for implant failure. Despite a pantheon of options available, post-operative dislocation remains a challenge especially in patients with risk factors for instability. The use of large diameter heads is proven to improve stability but there are concerns regarding wear rates, metal toxicity and recurrent dislocation in the presence of abductor dysfunction. With constrained liners there are concerns regarding device failure and aseptic loosening due to implant overload. Our dislocation rates of 1.9% and survivorship to date compare favourably with alternative techniques and are also in line with studies from France using implants of a similar design. In our hands, where there are risk factors for dislocation, the use of a dual-mobility implant has been very effective at both restoring and maintaining stability in patients undergoing revision THA.
